Earnings anticipation builds: Market participants on social media are closely tracking Gilead Sciences ahead of its quarterly results due after the close today. Analysts project revenue around $30.4 billion for the full year with EPS estimates holding steady despite recent peer performances in the sector.
Target price chatter: Recent analyst notes shared online highlight a consensus price target near $157, representing potential upside from current levels around $130. Discussions note the firm's consistent top-line delivery but flag questions around full-year EPS guidance following prior shortfalls.
Sector context emerges: Broader biotech earnings from peers like Merck and Pfizer have set a cautious tone, with investors weighing Gilead's pipeline progress against modest revenue growth expectations of about 3.8 percent. Sentiment remains focused on whether results will close the gap to higher targets.
Note: This discussion summary was generated from an AI condensation of post data.
Gilead Sciences Insider Trading Activity
Gilead Sciences insiders have traded $GILD stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 12 sales selling 175,640 shares for an estimated $25,319,875.
- JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 13 sales selling 68,000 shares for an estimated $9,617,516.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,000 shares for an estimated $2,481,646.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Gilead Sciences Revenue
Gilead Sciences had revenues of $7B in Q1 2026. This is an increase of 4.39% from the same period in the prior year.
You can track GILD financials on Quiver Quantitative's GILD stock page.
You can access data on GILD stock through the Quiver Quantitative API.
Gilead Sciences Congressional Stock Trading
Members of Congress have traded $GILD stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/06 and 0 sales.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Gilead Sciences Hedge Fund Activity
We have seen 992 institutional investors add shares of Gilead Sciences stock to their portfolio, and 992 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,326,800 shares (+9.6%) to their portfolio in Q1 2026, for an estimated $871,516,700
- BLACKROCK, INC. removed 4,184,605 shares (-3.4%) from their portfolio in Q1 2026, for an estimated $576,429,338
- BARCLAYS PLC removed 3,833,287 shares (-42.1%) from their portfolio in Q1 2026, for an estimated $528,035,284
- BANK OF AMERICA CORP /DE/ removed 3,142,684 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $432,904,721
- QUBE RESEARCH & TECHNOLOGIES LTD removed 2,425,986 shares (-95.2%) from their portfolio in Q1 2026, for an estimated $334,179,571
- WELLINGTON MANAGEMENT GROUP LLP removed 2,369,313 shares (-14.9%) from their portfolio in Q1 2026, for an estimated $326,372,865
- GOLDMAN SACHS GROUP INC added 2,316,632 shares (+26.5%) to their portfolio in Q1 2026, for an estimated $319,116,058
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Gilead Sciences Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/11/2026
To track analyst ratings and price targets for Gilead Sciences, check out Quiver Quantitative's $GILD forecast page.
Gilead Sciences Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 12 analysts offer price targets for $GILD in the last 6 months, with a median target of $165.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $166.0 on 07/08/2026
- Gregory Renza from Truist Securities set a target price of $156.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $120.0 on 07/07/2026
- Morten Herholdt from HSBC set a target price of $155.0 on 07/06/2026
- Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 07/06/2026
- Michael Okunewitch from Maxim Group set a target price of $165.0 on 05/20/2026
- Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
